Although most HDAC inhibitors have been developed for the hematological malignancies, an increasing number of HDAC inhibitors are investigated for the treatment of central nervous system (CNS) diseases such as brain cancers, Alzheimer’s disease, depression, and drug addiction6,21. This evidence concerns the gene HDAC9 and hematologic disorder.